Evaluating Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) as a novel drug target in Head and Neck Cancer

评估胰岛素样生长因子结合蛋白 3 (IGFBP3) 作为头颈癌新药物靶点

• 批准号: 466615
• 负责人: Fotiadou Iosifina
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466615&lang=en
• 关键词: Cancer Research; Cell Signalling; Crispr Editing; Functional Genomics; Head And Neck Squamous Cell Carcinoma; In Vivo Crispr Drop-Out Screening; In-Utero Lentiviral Microinjection Delivery Method; Insulin-Like Growth Factor Binding Proteins; Mouse Models

Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the deadliest and most prevalent cancers with rising incidence. The treatment options are non-selective and associated with toxicities and other adverse effects, thus highlighting the need for novel

头颈部鳞状细胞癌（HNSCC）是最致命和最普遍的癌症之一，发病率不断上升。治疗选择是非选择性的，并且与毒性和其他不良反应相关，因此突出了对新的治疗方法的需要。